Related Experiment Videos
Immunotoxins: an update
G R Thrush1, L R Lark, B C Clinchy
1Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235, USA.
Annual Review of Immunology
|January 1, 1996
Summary
Immunotoxins (ITs) show promise for treating cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS. Despite challenges like toxicity, ITs offer a potent therapeutic strategy for minimal disease.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Immunotoxins (ITs) have been investigated for two decades in treating various diseases.
- ITs combine a targeting component with a cytotoxic payload for selective cell killing.
- Advancements in molecular biology have improved IT design and efficacy.
Purpose of the Study:
- To review the therapeutic applications and potential of immunotoxins.
- To highlight the progress and challenges in immunotoxin therapy.
- To assess the promise of ITs in treating minimal residual disease.
Main Methods:
- Review of existing literature on immunotoxin development and clinical trials.
- Analysis of the components and mechanisms of action of immunotoxins.
- Evaluation of phase I/II clinical trial outcomes.
Main Results:
- Immunotoxins have demonstrated effectiveness in preclinical and early clinical studies.
- Newly developed monoclonal antibodies (MoAbs), toxins, and technologies enhance IT capabilities.
- Promising results have been observed in phase I/II clinical trials for various conditions.
Conclusions:
- Immunotoxin therapy holds significant promise for treating cancers and other immune-related diseases.
- Overcoming challenges such as non-specific toxicity and immunogenicity is crucial for broader application.
- ITs are a promising therapeutic option for minimal disease settings.